← All trials
NCT04893018
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Jun 30, 2025
- First posted
- May 19, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- University of California, San FranciscoOverall official - principal investigator
- Cancer Immunotherapy Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.